Learn More
Acute myeloid leukaemia is a highly malignant haematopoietic tumour that affects about 13,000 adults in the United States each year. The treatment of this disease has changed little in the past two decades, because most of the genetic events that initiate the disease remain undiscovered. Whole-genome sequencing is now possible at a reasonable cost and(More)
Most patients with acute myeloid leukaemia (AML) die from progressive disease after relapse, which is associated with clonal evolution at the cytogenetic level. To determine the mutational spectrum associated with relapse, we sequenced the primary tumour and relapse genomes from eight AML patients, and validated hundreds of somatic mutations using deep(More)
Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders that often progress to chemotherapy-resistant secondary acute myeloid leukemia (sAML). We used whole-genome sequencing to perform an unbiased comprehensive screen to discover the somatic mutations in a sample from an individual with sAML and genotyped the loci containing these mutations(More)
Next-generation sequencing has been used to infer the clonality of heterogeneous tumor samples. These analyses yield specific predictions-the population frequency of individual clones, their genetic composition, and their evolutionary relationships-which we set out to test by sequencing individual cells from three subjects diagnosed with secondary acute(More)
Therapy-related acute myeloid leukaemia (t-AML) and therapy-related myelodysplastic syndrome (t-MDS) are well-recognized complications of cytotoxic chemotherapy and/or radiotherapy. There are several features that distinguish t-AML from de novo AML, including a higher incidence of TP53 mutations, abnormalities of chromosomes 5 or 7, complex cytogenetics and(More)
1. De novo AML in an adult patient less than 60 years old. Patients enrolled in the study were greater than 18 years of age, and with no antecedent history of myelodysplastic syndrome or prior chemotherapy or radiation therapy for cancer, since treatment‐related AML may have a different genetic basis than de novo AML. Further, several Cooperative Group(More)
  • J L Gangloff-Kaufmann, C Pichler, New York, Jody Gangloff-Kaufmann, Cathy Pichler, Waheed Bajwa +20 others
  • 2008
of the New York State IPM Program, which develops sustainable ways to manage pests and helps people to use methods that minimize environmental, health, and economic risks. For more information or web-based copies of this guide (IPM No. 618) see the New York State IPM Program website at Cornell Cooperative Extension provides equal program and employment(More)
# These authors contributed equally to this work. Therapy-related acute myeloid leukemia (t-AML) and therapy-related myelodysplastic syndrome (t-MDS) are well-recognized complications of cytotoxic chemotherapy and/or radiotherapy 1. There are several features that distinguish t-AML from de novo AML including a higher incidence of TP53 mutations 2,3 ,(More)
  • 1